Kiadis Pharma in ATIR licensing pact with Hospira

Kiadis Pharma claims that ATIR will enable a mismatched family member to act as donor and is being developed to reduce transplant related mortality caused by infections and graft-versus-host disease.

ATIR has orphan drug designations from both the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

As per the agreement, upon successful development and commercialization of ATIR in the European market, Kiadis Pharma can receive additional milestone payments and is entitled to royalties on product sales.

Kiadis Pharma CEO Manja Bouman said that Hospira’s commitment to commercialize ATIR will ultimately accelerate making this lifesaving product available for patients.